Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (750)	10/2/2007 10:38:08 AM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Some more comments on the combo: Introgen Announces Publication of Research Showing Promising Activity of INGN 241 Combined with Velcade(R) in Ovarian Cancer Tuesday October 2, 8:30 am ET AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN - News) announced today the publication of data from a preclinical study demonstrating the combination of INGN 241, Introgen's mda-7/IL-24 cancer product candidate, and Velcade® (Bortezemib) resulted in increased tumor cell killing in human ovarian cancer cells. The results from the study appeared in an advanced on-line article in Cancer Gene Therapy and provide a new molecularly targeted approach to specifically destroy cancer cells. The research was performed in the laboratory of Dr. Rajagopal Ramesh, associate professor in the Department of Thoracic and Cardiovascular Surgery at M.D. Anderson Cancer Center. "This study shows that prolonging expression and function of tumor suppressor therapies, such as INGN 241, results in increased destruction of cancer cells," said Dr. Ramesh. "Having discovered a fundamental facet of MDA-7 regulation advances the goal of being able to defeat ways that cancer cells survive, enabling us to outsmart them." Study Results Researchers identified the degradation pathway for the MDA-7 tumor suppressor protein that is the active component of INGN 241. They showed that co-administration of INGN 241 and Velcade, a known protein degradation inhibitor, further elevated MDA-7 protein levels and caused a significant increase in killing of ovarian cancer cells. Velcade is also known to prolong expression of other tumor suppressor proteins such as p53. Late last year, Introgen announced the worldwide, exclusive license to a family of patent applications, one of which covers the combination of Introgen's tumor suppressor product candidates and proteasome inhibitors, which can increase therapeutic functionality, such as Velcade® (Bortezemib). Snip The stock is up > 3% on low volume. It needs to get back above $4.50 <g> bigcharts.marketwatch.com Bernard P.S. Thanks Tom & Elizabeth for the <Gs>